Venture Visionary Partners LLC Purchases 1,358 Shares of Thermo Fisher Scientific Inc. $TMO

Venture Visionary Partners LLC lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 40.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,699 shares of the medical research company’s stock after acquiring an additional 1,358 shares during the quarter. Venture Visionary Partners LLC’s holdings in Thermo Fisher Scientific were worth $2,723,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in TMO. Whalerock Point Partners LLC boosted its holdings in shares of Thermo Fisher Scientific by 0.8% in the 4th quarter. Whalerock Point Partners LLC now owns 13,843 shares of the medical research company’s stock worth $8,021,000 after buying an additional 105 shares during the last quarter. Panagora Asset Management Inc. boosted its holdings in shares of Thermo Fisher Scientific by 11.3% in the 4th quarter. Panagora Asset Management Inc. now owns 6,098 shares of the medical research company’s stock worth $3,533,000 after buying an additional 618 shares during the last quarter. Piedmont Capital Management LLC NC purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter worth about $322,000. Sargent Investment Group LLC purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter worth about $437,000. Finally, South Plains Financial Inc. boosted its holdings in shares of Thermo Fisher Scientific by 1.1% in the 4th quarter. South Plains Financial Inc. now owns 2,300 shares of the medical research company’s stock worth $1,333,000 after buying an additional 26 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on TMO. Stifel Nicolaus cut their target price on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating for the company in a research report on Friday, April 24th. Weiss Ratings reiterated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Wednesday, April 8th. Robert W. Baird lowered their price target on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Jefferies Financial Group raised shares of Thermo Fisher Scientific to a “strong-buy” rating in a report on Friday, April 24th. Finally, Barclays lowered their price target on shares of Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating on the stock in a report on Tuesday, April 14th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $608.95.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the sale, the chief operating officer owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Up 0.8%

Shares of NYSE TMO opened at $473.08 on Tuesday. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $643.99. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15. The firm’s 50 day simple moving average is $478.75 and its two-hundred day simple moving average is $526.39. The stock has a market capitalization of $175.81 billion, a P/E ratio of 26.01, a PEG ratio of 2.08 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. The firm had revenue of $11.01 billion during the quarter, compared to analyst estimates of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The business’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, analysts expect that Thermo Fisher Scientific Inc. will post 24.85 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be paid a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, June 15th. Thermo Fisher Scientific’s dividend payout ratio is 10.34%.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.